April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Therapeutic Experience With Infliximab In Patient With Juvenile Idiopathic Arthritis Associated Uveitis
Cesare Pirondini; Chiara Mapelli; Alfonso Spinello; Edoardo Villani; Elisabetta Vismara; Paolo Vercellesi; Antonella Petaccia; Fabrizia Corona; Roberto Ratiglia
Author Affiliations & Notes
  • Cesare Pirondini
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Chiara Mapelli
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Alfonso Spinello
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Edoardo Villani
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Elisabetta Vismara
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Paolo Vercellesi
    Rheumathology Pediatric,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Antonella Petaccia
    Rheumathology Pediatric,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Fabrizia Corona
    Rheumathology Pediatric,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Roberto Ratiglia
    Ophthalmology,
    Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano University of Milan, Milano, Italy
  • Footnotes
    Commercial Relationships  Cesare Pirondini, None; Chiara Mapelli, None; Alfonso Spinello, None; Edoardo Villani, None; Elisabetta Vismara, None; Paolo Vercellesi, None; Antonella Petaccia, None; Fabrizia Corona, None; Roberto Ratiglia, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Therapeutic Experience With Infliximab In Patient With Juvenile Idiopathic Arthritis Associated Uveitis
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Cesare Pirondini, Chiara Mapelli, Alfonso Spinello, Edoardo Villani, Elisabetta Vismara, Paolo Vercellesi, Antonella Petaccia, Fabrizia Corona, Roberto Ratiglia; Therapeutic Experience With Infliximab In Patient With Juvenile Idiopathic Arthritis Associated Uveitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4258.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To describe our experience using infliximab for the treatment of juvenile idiopathic arthritis (JIA) associated uveitis.

Methods: : We performed a retrospective chart review of 79 consecutive JIA patients observed between January 2005 and November 2010 at the Ophthalmology Department of Ospedale Maggiore in Milan and we analyzed the notes of those treated with infliximab for refractory uveitis. All patients underwent routinely complete ophthalmologic exam including best corrected visual acuity (BCVA), slit-lamp biomicroscopy, IOP measurement, dilated fundus examination, Optical Coherence Tomography. All patients underwent also a regular complete rheumatological evaluation at our Rheumatology Pediatric Departement.Outcome measures included incidence of uveitis recurrences, BCVA, macular thickness, tapering/discontinuation of systemic or topical treatment and infliximab side effects.

Results: : Uveitis occurred in 21/79 (26%) JIA patients (3 males, 18 females); among these, 5 children (1 male, 4 females) were started on infliximab (5mg/kg i.v. at week 0, 2, 4, followed by 6/8 weekly infusion according to clinical response) for refractory uveitis.Mean duration of ocular disease at the beginning of therapy was 101 months (49-130) and mean follow-up on infliximab was 15 months (12-19).Recurrences of uveitis decreased in 3patients (4 eyes) while minimal or no response was observed in 2 children. Visual acuity remained stable in all cases.Two patients presented macular edema (ME) when switched to infliximab and showed a remarkable reduction of the macular thickness after treatment; 1eye developed ME 1 year after treatment beginning.Systemic (steroids and methotrexate) treatment was tapered in 3 patients during the follow up period, topical steroids were tapered in 2 patients (3 eyes) and discontinued in 1.Two patients discontinued infliximab for treatment failure represented by persistent inflammatory status and/or development of macular edema.No systemic side effects related to inflixmab were observed.

Conclusions: : Infliximab appears to be safe in children, and may represents a useful option for the treatment of refractory JIA associated uveitis.

Keywords: uveitis-clinical/animal model • inflammation • edema 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept